Motilal Oswal Initiates Buy On Midcap Pharma Stock, Sees 15% Potential Upside
Leading broking firm Motilal Oswal reiterate Buy on Eris Lifesciences Ltd., a midcap Pharma sector firm. The brokerage assigns a target price of Rs. 720/share on the stock, claiming an upside of 15% from its current level. The company is engaged ...